Scandion Oncology A/S (8VY.F)
- Previous Close
0.1135 - Open
0.1125 - Bid 0.1155 x --
- Ask 0.1415 x --
- Day's Range
0.1125 - 0.1180 - 52 Week Range
0.0817 - 0.4245 - Volume
610 - Avg. Volume
0 - Market Cap (intraday)
5.177M - Beta (5Y Monthly) 1.28
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1300 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Scandion Oncology A/S, a clinical-stage biotechnology company, discovers and develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase II clinical trial for the treatment of colorectal cancer; and in Phase I clinical trial for treating pancreatic cancer, as well as in preclinical studies for other cancer indications. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark.
www.scandiononcology.comRelated News
Performance Overview: 8VY.F
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 8VY.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 8VY.F
Valuation Measures
Market Cap
5.07M
Enterprise Value
1.58M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.11
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.04
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-46.19%
Return on Equity (ttm)
-77.29%
Revenue (ttm)
446k
Net Income Avi to Common (ttm)
-39.2M
Diluted EPS (ttm)
-0.1300
Balance Sheet and Cash Flow
Total Cash (mrq)
26.52M
Total Debt/Equity (mrq)
1.60%
Levered Free Cash Flow (ttm)
-40.11M
Company Insights: 8VY.F
8VY.F does not have Company Insights